Sofosbuvir for the treatment of hepatitis C specifically in Asian American communities was well-tolerated, according to a new report.
Investigators from NYU School of Medicine identified 186 eligible patients from across 11 sites in the United States and enrolled them in their study in order to evaluate sofosbuvir-based regimens in a cohort of Asian Americans. The study authors said that there is only limited data about treatment outcomes in Asian Americans with hepatitis C.
The study period lasted from December 2013 through June 2017 and the investigators measured sustained virologic response rates at 12 and 24 weeks post-treatment. The study authors also examined secondary endpoints of safety by tolerability and adverse events.